Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic thromboembolic pulmonary hypertension, according to results published in European ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sotatercept for 24 weeks resulted in a reduction in pulmonary vascular resistance among patients ...

Uptravi may reduce blood pressure in the lungs of children with pulmonary arterial hypertension, according to a meta-analysis ...

The FDA approved a Phase 2b trial of CS1, a new PAH therapy being tested for its impact on lung vessel resistance and exercise capacity.

An ongoing multicenter study in Japan will evaluate reductions in pulmonary vascular resistance 8 months after initiating the combination therapy in pulmonary arterial hypertension. An ongoing study ...

BARCELONA, Spain—New guidelines for the diagnosis and treatment of pulmonary hypertension (PH), released at the recent European Society of Cardiology (ESC) Congress 2022, include a new hemodynamic ...

Merck MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered ...

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention. A new paper has highlighted the significant impact of type 2 ...